Neoplasms

All Conditions

Musculoskeletal Diseases

Rare Diseases

Craniopharyngioma

Adamantinoma

Ameloblastoma

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Bone Neoplasms

Bone Diseases

Neuroepithelioma

Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).

If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.

Tumor and Blood Specimens

Todd Hankinson, MD

New data suggests that the current treatment for pediatric adamantinomatous craniopharyngioma (CPA) may not be as effective as it could be.

Current treatment regimens for pediatric CPA are limited to surgery and radiation therapy. This pilot study seeks to identify biologically rational therapeutics for the medical treatment of adamantinomatous CPA by confirming the overexpression of specific molecules.

Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy

Advancing Treatment for Pediatric Craniopharyngioma: Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy

Investigators will identify potential therapeutic targets through mRNA expression.

Investigators will identify potential therapeutic targets through microarray analysis.

Investigators will identify potential therapeutic targets immunohistochemistry.

Investigators will identify potential therapeutic targets through quantitative PCR.

Investigators will also perform immunostaining for beta-catenin and use DNA SNaPshot analysis to determine what parts of the tumor are responsible for observed gene signatures.

The amount of time the patient survives with or without the disease.

The amount of time the patient survives without advancement of disease.

With regard to visual deficits, investigators will compare the rates of functional blindness, unilateral blindness, and visual field deficit.

With regard to pituitary function, investigators will assess patients based on the quality of life impairment that is associated with their dysfunction. Assessment will be divided among 4 groups:

1. No dependence on hormone supplementation or evidence of diabetes insipidus
2. Dependence on 1 or 2 hormone supplements without diabetes insipidus
3. The presence of diabetes insipidus with or without the need for 2 or fewer hormone supplements
4. Diabetes Insipidus with panhypopituitarism

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy	NCT03610906	Craniopharyngio...	Tumor and Blood...	30 Days - 21 Years	University of Colorado, Denver
Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy	NCT03610906	Craniopharyngio...	Tumor and Blood...	30 Days - 21 Years	University of Colorado, Denver

Spots Global Cancer Trial Database for tumor and blood specimens